This study is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to evaluate the difference in efficacy of Butylphthalide Sodium Chloride Injection treatment initiated early (\<3 hours) versus late (3-6 hours) in patients with acute ischemic stroke. The aim is to determine the optimal timing window for neuroprotective therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
204
Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\<3 hours) and a late initiation group (3-6 hours).
Xiangya Hospital, Central South University
Changsha, Hunan, China
Xiangya Hospital, Central South University
Changsha, China
The proportion of participants with an mRS score of 0-2
Time frame: 90±7 days post-randomization
Proportion of participants with an mRS score of 0-1
Time frame: 90±7 days post-randomization
Changes in NIHSS scores
Time frame: at 6±1 days and 12±2 days compared to baseline
Proportion of participants with an improvement of ≥4 points in NIHSS scores
Time frame: at 6±1 days and 12±2 days
Early neurological deterioration
Time frame: at 24±2 hours and 6±1 days post-randomization
Proportion of participants with ineffective recanalization
Time frame: at 90±7 days post-randomization
Proportion of participants with recurrent ischemic stroke
Time frame: at 90±7 days post-randomization
Proportion of combined vascular events (recurrent stroke, myocardial infarction, and vascular death)
Time frame: at 90±7 days post-randomization
Difference in cerebral infarction volume size
Time frame: between baseline and 12±2 days post-randomization
Quality of life (EQ-5D) scores
Time frame: at 90±7 days post-randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.